

DESIGNAÇÃO DO PROJETO | New Technologies for three Health Challenges of Modern Societies: Diabetes, Drug Abuse and Kidney Diseases

CÓDIGO DO PROJETO | NORTE-01-0145-FEDER-000024

OBJETIVO PRINCIPAL | Over the past 20 years, Portugal has experienced a very marked scientific and technological development. This evolution is well portrayed in the increase in the number of new PhDs per year, number of researchers per thousand active workers, number of publications and, to some extent, number of patents. The Northern region of Portugal has played an important role in this entire process, with the University of Porto assuming a leading position, well anchored in its associated laboratories. UCIBIO with around 300 researchers (187 Ph.D, roughly half working in Porto), has been one of such laboratories, combining key expertizes in the fields of Chemistry, Biochemistry & Molecular Biology, and Pharmacology & Pharmacy. Its key strength lies on the broad scope of fundamental and applied research to address questions at atomic, molecular, sub-cellular and cellular levels, including cell-to-cell interactions and population evolutionary dynamics. Scientific activity is internationally recognized and evidenced by over 2,400 articles published during 2010-2014.

The last 5 years have made clear that the large continued investment in science and technology in Portugal has not produced yet direct social and economical benefits of relevance. We believe that in the future, Portugal will only remain competitive in a global economy having research, technological development and innovation as cornerstones. Therefore, we have been devising strategies to apply the knowledge, synergies and critical mass gathered over the last few years, in the implementation of interdisciplinary working teams, strongly competitive at the international level, dedicated to solving problems with direct social and economic impact, in the interface of Chemistry, Biology and Pharmaceutical Sciences.

In this sense, the present project aims to strength UCIBIO's efforts of developing three highly competitive multidisciplinary research lines in areas of strategic importance.

ENTIDADE BENEFICIÁRIA | ICETA

DATA DE APROVAÇÃO: 01-04-2016 / **DATA DE INICIO:** 01-04-2016 / **DATA DE FIM:** 30-03-2020

INVESTIMENTO

CUSTO TOTAL ELEGIVEL | 3 318 431,20 €

APOIO FINANCEIRO DA UNIÃO EUROPEIA | 85%

FUNDOS PRÓPRIOS | 15%